International CML foundation's Newsletter June 2022
GOLDMAN PRIZE- Professor Andreas Hochhaus (Germany)
ROWLEY PRIZE- Professor Oliver Hantschel (Germany)
Jane Apperley- 40-years in medicine
Ravi Bhatia, MD- The leukaemia stem cell in its niche- the quest for cure
'Among challenges of TFR, it is also included the better identification of patients who have a high probability of relapsing compared with those who experience a successful TFR. Some of the most promising data involve the field of immunology, especially T-cell cytotoxicity and NK cell effects. In several studies, NK cell numbers or functional subsets of NK cells were shown to be higher in patients who maintain TFR than in those who lose molecular response during TKI discontinuation.'
This review will present the current studies that are helping to increase our understanding of the biological factors (clinical and non-clinical, cellular, and molecular) that may determine TKI discontinuation success
https://link.springer.com/article/10.1007/s11912-022-01228-w
The evidence that vitamin D has important health benefits continued to increase in 2021. In particular, the benefits in reducing risk of SARS-CoV-2 infection and COVID-19 became more robust, as did those for CVD. The evidence clearly points to the healthy range of 25(OH)D as being 30-40 ng/ml, with additional evidence for the optimal range being 40-60 ng/ml. Due to modern lifestyles, it is very difficult to achieve those levels from solar UVB exposure and diet. The most efficient way to raise serum 25(OH)D is to supplement with vitamin D3, of at least 5000 IU/d, and up to 10,000 IU/d.
CML Advocates Network have provided a helpful summary of 63rd ASH meeting: CML abstracts and presentations
https://www.cmladvocates.net/download/scientific-conferences/ash-2021/1152-ash-2021-cml-report/file
Discover how much vitamin D may be necessary to help you achieve your target vitamin D level. The new D*calculator provides two options for increasing your vitamin D levels – a “Loading Dose” and a “Maintenance Dose” allowing users to choose how quickly they would like to achieve their desired levels.
A. Hochhaus, M. Baccarani, .... R. Hehlmann
In this issue of Blood, Cortes et al demonstrate that the optimal benefit-to-risk outcome for ponatinib-treated patients with chronic myeloid leukemia (CML) who had failed prior therapy was a starting dose of 45 mg, which was reduced to 15 mg upon attainment of a response.
CML Highlights of the 63rd ASH Annual Meeting
Join our two experts to hear about key aspects of the scientific program such as the Live Q&A Session on CML: 'Success breeds more success', the ASH-FDA Joint Symposium on newly approved drugs: 'Treatment landscape in the era of novel therapies' and oral and poster abstracts on basic and translational research in CML, mechanisms of resistance and expanded therapies and progress with response predictors and TKI discontinuation.
iCMLF Knowledge Centre an interactive online resource providing educational content on CML patient management, options for molecular monitoring and practical considerations of BCR-ABL1 testing